CACLP Expo Ended Perfectly, Biotest’s Exhibition Conclusion.
Mar 26, 2025
Leave a message
On March 21, 2025, the 22nd China International Exhibition for Clinical Laboratory and Diagnostic Medicine (CACLP) opened at the Hangzhou Convention and Exhibition Center, attracting over 1,000 exhibitors from more than 40 countries and regions. The event showcased the entire IVD industry chain, featuring advancements in laboratory medicine, transfusion medicine, independent laboratories, and related fields through academic exchanges and product exhibitions.
Spotlight on Breakthrough Innovations
As a leading innovator in the IVD sector, Biotest made a striking appearance with cutting-edge products and solutions, engaging with global partners to explore industry trends and demonstrate its technological leadership. Beyond conventional reagent testing products, Biotest unveiled its groundbreaking new series: Microfluidic technologies ,Diagpal and Diagpal Se diagnostic platforms.
Diagpal
Lateral Flow Reader: A clear image of the test is captured by a high-resolution image recognition system, from which the image is accurately analysed using image enhancement, noise reduction and other technologies, and combined with a machine to interpret the results.
Microfluidic Immunofluorescence Analysis System
The 3rd Generation Rapid Immunoassay:A microfluidic chip is a pattern of microchannels, molded or engraved. It integrates and automates multiple high-resolution laboratory techniques such as synthesis and analysis of chemicals or fluid testing into a system that fits on a chip. Microfluidics have diverse assets: faster reaction time, enhanced analytical sensitivity, enhanced temperature control, portability, easier automation and parallelization, integration of lab routines in one device.
Diagpal SE
Lateral Flow Reader: Compact design with a screenthat can directly display results,suitable for roadside testing.Night Time Roadside Testing
Collaborating for a Healthier Future
CACLP 2025 was not just a platform for technological display but also an opportunity to foster industry collaboration. Staying true to its mission-"Making Diagnostics More Accurate and Accessible"-Biotest will continue to drive the advancement and global adoption of IVD solutions, working hand-in-hand with partners to enhance healthcare worldwide.